B‑cell lymphoma‑associated hemophagocytic lymphohistiocytosis: A case report

Ojo,Ademola S.; Asemota,Joseph; Ojukwu,Somtochukwu; Rajeh,Ahmad; Bot,Amina; Smith,Caitlyn J.; Laziuk,Katsiaryna; Saleh,Mohammed

doi:10.3892/ol.2022.13365

B‑cell lymphoma‑associated hemophagocytic lymphohistiocytosis: A case report

Authors:
- Ademola S. Ojo
- Joseph Asemota
- Somtochukwu Ojukwu
- Ahmad Rajeh
- Amina Bot
- Caitlyn J. Smith
- Katsiaryna Laziuk
- Mohammed Saleh
View Affiliations

Affiliations: Department of Internal Medicine, Howard University Hospital, Washington, DC 20060, USA, Department of Medicine, School of Medicine, University of Missouri, Columbia, MO 65212, USA, Department of Pathology and Anatomical Sciences, School of Medicine, University of Missouri, Columbia, MO 65212, USA
Published online on: June 7, 2022 https://doi.org/10.3892/ol.2022.13365
Article Number: 246
Copyright: © Ojo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life‑threatening condition characterized by an exaggerated but dysregulated immune response resulting in hyperinflammation, with a potential for progression to multiple organ dysfunction and failure. Infectious diseases, inflammatory disorders, malignancies and immunodeficiency syndromes are known triggers of HLH in adults. The present study reported the case of a middle‑aged man with HLH triggered by B‑cell lymphoma who was successfully treated with dexamethasone; etoposide, prednisone, vincristine, cyclophosphamide, hydroxy‑doxorubicin and rituximab chemotherapy; and multiple intrathecal methotrexate with a good outcome.

View Figures

View References

1	Filipovich A, McClain K and Grom A: Histiocytic disorders: Recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 16 (1 Suppl):S82–S89. 2010. View Article : Google Scholar
2	Hayden A, Park S, Giustini D, Lee AY and Chen LY: Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review. Blood Rev. 30:411–420. 2016. View Article : Google Scholar : PubMed/NCBI
3	Takeuchi O and Akira S: Pattern recognition receptors and inflammation. Cell. 140:805–820. 2010. View Article : Google Scholar
4	Pachlopnik Schmid J, Côte M, Ménager MM, Burgess A, Nehme N, Ménasché G, Fischer A and de Saint Basile G: Inherited defects in lymphocyte cytotoxic activity. Immunol Rev. 235:10–23. 2010. View Article : Google Scholar : PubMed/NCBI
5	Risma K and Jordan MB: Hemophagocytic lymphohistiocytosis: Updates and evolving concepts. Curr Opin Pediatr. 24:9–15. 2012. View Article : Google Scholar : PubMed/NCBI
6	Bichon A, Bourenne J, Allardet-Servent J, Papazian L, Hraiech S, Guervilly C, Pauly V, Kaplanski G, Mokart D, Gainnier M and Carvelli J: High mortality of HLH in ICU regardless etiology or treatment. Front Med (Lausanne). 8:7357962021. View Article : Google Scholar : PubMed/NCBI
7	Esteban YM, de Jong JLO and Tesher MS: An overview of hemophagocytic lymphohistiocytosis. Pediatr Ann. 46:e309–e313. 2017. View Article : Google Scholar : PubMed/NCBI
8	Madkaikar M, Shabrish S and Desai M: Current updates on classification, diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH). Indian J Pediatr. 83:434–443. 2016. View Article : Google Scholar : PubMed/NCBI
9	Spessott WA, Sanmillan ML, McCormick ME, Patel N, Villanueva J, Zhang K, Nichols KE and Giraudo CG: Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXBP2 that inhibit SNARE-mediated membrane fusion. Blood. 125:1566–1577. 2015. View Article : Google Scholar : PubMed/NCBI
10	Jordan MB, Allen CE, Weitzman S, Filipovich AH and McClain KL: How I treat hemophagocytic lymphohistiocytosis. Blood. 118:4041–4052. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA and Bosch X: Adult haemophagocytic syndrome. Lancet. 383:1503–1516. 2014. View Article : Google Scholar
12	Shabbir M, Lucas J, Lazarchick J and Shirai K: Secondary hemophagocytic syndrome in adults: A case series of 18 patients in a single institution and a review of literature. Hematol Oncol. 29:100–106. 2011. View Article : Google Scholar
13	Rivière S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O and Fardet L: Reactive hemophagocytic syndrome in adults: A retrospective analysis of 162 patients. Am J Med. 127:1118–1125. 2014. View Article : Google Scholar
14	Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, et al: Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 122:2857–2866. 2016. View Article : Google Scholar : PubMed/NCBI
15	Gu Y, Shore RE, Arslan AA, Koenig KL, Liu M, Ibrahim S, Lokshin AE and Zeleniuch-Jacquotte A: Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: A prospective study. Cancer Causes Control. 21:1323–1333. 2010. View Article : Google Scholar
16	Vanmaris RMM and Rijkers GT: Biological role of the soluble interleukin-2 receptor in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 34:122–129. 2017.PubMed/NCBI
17	Chang TY, Jaffray J, Woda B, Newburger PE and Usmani GN: Hemophagocytic lymphohistiocytosis with MUNC13-4 gene mutation or reduced natural killer cell function prior to onset of childhood leukemia. Pediatr Blood Cancer. 56:856–858. 2011. View Article : Google Scholar : PubMed/NCBI
18	Karlsson T: Secondary haemophagocytic lymphohistiocytosis: Experience from the Uppsala university hospital. Ups J Med Sci. 120:257–262. 2015. View Article : Google Scholar
19	Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J and Janka G: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 48:124–131. 2007. View Article : Google Scholar : PubMed/NCBI
20	Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P and Hejblum G: Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 66:2613–2620. 2014. View Article : Google Scholar
21	Debaugnies F, Mahadeb B, Nagant C, Meuleman N, De Bels D, Wolff F, Gottignies P, Salaroli A, Borde P, Voué M and Corazza F: Biomarkers for early diagnosis of hemophagocytic lymphohistiocytosis in critically Ill patients. J Clin Immunol. 41:658–665. 2021. View Article : Google Scholar
22	Hu S, Bansal P, Lynch D, Rojas Hernandez CM and Dayao Z: Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: A case report and review of the literature. J Med Case Rep. 10:3652016. View Article : Google Scholar : PubMed/NCBI
23	Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, et al: Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 368:1408–1416. 2013. View Article : Google Scholar : PubMed/NCBI
24	Chellapandian D, Das R, Zelley K, Wiener SJ, Zhao H, Teachey DT and Nichols KE; EBV-HLH Rituximab Study Group, : Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 162:376–382. 2013. View Article : Google Scholar
25	University of Michigan Rogel Cancer Center, . A pilot study of ruxolitinib in secondary hemophagocytic syndrome. https://clinicaltrials.gov/ct2/show/NCT02400463?cond=NCT02400463&draw=2&rank=1January 28–2022
26	Children's Hospital of Philadelphia, . Tocilizumab and hemophagocytic lymphohistiocytosis (HLH). https://clinicaltrials.gov/ct2/show/NCT02007239?cond=NCT02007239&draw=2&rank=1January 28–2022
27	M.D. Anderson Cancer Center, . Alemtuzumab or tocilizumab in combination with etoposide and dexamethasone for the treatment of adult patients with hemophagocytic lymphohistiocytosis. https://clinicaltrials.gov/ct2/show/NCT02385110?cond=NCT02385110&draw=2&rank=1January 28–2022